Skip to main content
Ovarian Cancer
EFFORT Study of Adavosertib with or without Olaparib in Women with PARP-Resistant Ovarian Cancer
Read More
Ovarian Cancer
Final Overall Survival Results from the LIGHT Study of Olaparib Treatment in Platinum-Sensitive Relapsed Ovarian Cancer by BRCA Mutation and Homologous Recombination Deficiency Status
Read More
Ovarian Cancer
Phase 3b OPINION Primary Analysis of Olaparib Maintenance Monotherapy for Nongermline BRCA1/2-Mutated Platinum-Sensitive Relapsed Ovarian Cancer
Read More
Biosimilars
Comparative Efficacy and Safety of the Bevacizumab Biosimilar MIL60 versus Bevacizumab Reference in Patients with Advanced or Recurrent Nonsquamous NSCLC
Read More
Biosimilars
Same-Day Pegfilgrastim or PFG-cbqv Prophylaxis of Chemotherapy-Induced Neutropenia in Bendamustine plus Rituximab and CHOP±R Regimens in Patients with Lymphoma and CLL
Read More
Biosimilars
Same-Day Pegfilgrastim or Pegfilgrastim-cbqv Prophylaxis in miniCHOP Chemotherapy-Based Regimens for Non-Hodgkin Lymphoma
Read More
Biosimilars
Demographics and Clinical Characteristics of Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-awwb in Real-World Oncology Clinics
Read More
Biosimilars
Impact of the Oncology Care Model on Use of Bone Supportive Medications, Antiemetics, and Growth Factors
Read More
Biosimilars
Cost-Efficiency Analysis of Conversion from Pegfilgrastim with On-Body Injector to Pegfilgrastim-jmdb to Provide Budget-Neutral Expanded Access to Prophylaxis and Treatment
Read More
Biosimilars
Pharmacokinetic Study Comparing SB12 (Eculizumab Biosimilar) with Reference Eculizumab in Healthy Volunteers
Read More
Page 68 of 196
Results 671 - 680 of 1953